Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma.
The immune system is subject to destruction and dysfunction as a result of attacks by pathogenic and environmental agents. In addition, many clinical situations exist in which it is desirable to stimulate or suppress the immune system. The present study evaluated the screening efficacy of flow cytometric lymphocyte subset typing in peripheral blood mononuclear cells from healthy individuals (HI) and from patients with non-Hodgkin lymphoma (NHL) treated with different concentrations of FR-91, a standardized lysate of microbial cells belonging to the Bacillus genus, and in vitro cytokine production. Increased expression of subset markers (CD3, CD4, CD8) in NHL and CD3 in HI suggests an immunomodulating effect of FR-91. In addition the results of cytokine production also demonstrated a clear effect of FR-91 on both populations. A significant increase of IL-6, IL-12, IFN-gamma and TNF-alpha was observed in the HI group after treatment with FR-91. In a similar manner an increase of IL-2, IL-6, IL-12, IFN-gamma and TNF-alpha was also observed in the NHL group. In conclusion FR-91 seems to affect lymphocyte subpopulations, in vitro cytokine production, as well as mitogen-induced lymphocyte activation in a dose-dependent manner in both healthy individuals and NHL patients.
Lombardi
V R M
VR
Departamento de Inmunología Celular, Euroespes Biotecnologia, La Coruña, 15166 Bergondo, Spain. biotecnologia@ebiotec.com
Martínez
E
E
Chacón
R
R
Etcheverría
I
I
Cacabelos
R
R
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000328:Adult; D000704:Analysis of Variance; D015703:Antigens, CD / Q000097:blood; D001407:Bacillus / Q000737:chemistry / Q000276:immunology*; D002457:Cell Extracts / Q000276:immunology / Q000494:pharmacology; D003208:Concanavalin A / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D007378:Interleukins / Q000096:biosynthesis / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology*; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets / Q000276:immunology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000276:immunology* / Q000628:therapy; D008875:Middle Aged; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D002457:Cell Extracts; D007378:Interleukins; D003208:Concanavalin A